How much revenue did Pharmaust generate this year?
Pharmaust has achieved a revenue of 3.9 M AUD this year.
Pharmaust Revenue 2024
Pharmaust Revenue
3.9 M AUD
Ticker
PAA.AX
ISIN
AU000000PAA1
WKN
A0DNJ3
In 2024, Pharmaust's sales reached 3.9 M AUD, a -13.53% difference from the 4.51 M AUD sales recorded in the previous year.
The Pharmaust Revenue history
| YEAR | REVENUE (undefined AUD) | GROSS MARGIN (%) |
|---|---|---|
| 2023 | 3.9 | 79,81 |
| 2022 | 4.51 | 93,03 |
| 2021 | 3.67 | 93,86 |
| 2020 | 4.12 | 94,03 |
| 2019 | 4.36 | 92,36 |
| 2018 | 3.3 | 91,22 |
| 2017 | 3.33 | 89,78 |
| 2016 | 2.75 | 91,49 |
| 2015 | 2.42 | 91,41 |
| 2014 | 2.01 | 88,56 |
| 2013 | 1.72 | 87,21 |
| 2012 | 1.63 | 88,96 |
| 2011 | 1.6 | 91,25 |
| 2010 | 1.94 | 89,18 |
| 2009 | 3.73 | 94,91 |
| 2008 | 2.98 | 76,17 |
| 2007 | 7.19 | 58,00 |
| 2006 | 6.9 | 71,59 |
| 2005 | 3.28 | 59,76 |
| 2004 | 0.51 | 72,55 |
Pharmaust Revenue, EBIT, Net Income AU000000PAA1 · A0DNJ3
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Pharmaust, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pharmaust from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pharmaust’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Pharmaust. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Pharmaust’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Pharmaust’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pharmaust’s growth potential.
Pharmaust Revenue, EBIT and net profit per share
| Date | Pharmaust Revenue | Pharmaust EBIT | Pharmaust Net Income |
|---|---|---|---|
| 2023 | 3.9 M undefined | -2.62 M undefined | -6.21 M undefined |
| 2022 | 4.51 M undefined | -1.62 M undefined | -1.71 M undefined |
| 2021 | 3.67 M undefined | -1.26 M undefined | -1.34 M undefined |
| 2020 | 4.12 M undefined | -1.24 M undefined | -1.36 M undefined |
| 2019 | 4.36 M undefined | -1.5 M undefined | -1.55 M undefined |
| 2018 | 3.3 M undefined | -2.49 M undefined | -2.52 M undefined |
| 2017 | 3.33 M undefined | -1.28 M undefined | -1.34 M undefined |
| 2016 | 2.75 M undefined | -1.82 M undefined | -3.93 M undefined |
| 2015 | 2.42 M undefined | -1.92 M undefined | -1.93 M undefined |
| 2014 | 2.01 M undefined | -1.32 M undefined | -1.32 M undefined |
| 2013 | 1.72 M undefined | -610,000 undefined | -510,000 undefined |
| 2012 | 1.63 M undefined | -880,000 undefined | -4.26 M undefined |
| 2011 | 1.6 M undefined | -790,000 undefined | -5.8 M undefined |
| 2010 | 1.94 M undefined | -330,000 undefined | -440,000 undefined |
| 2009 | 3.73 M undefined | 1.35 M undefined | -180,000 undefined |
| 2008 | 2.98 M undefined | -2.38 M undefined | -5.77 M undefined |
| 2007 | 7.19 M undefined | -5.14 M undefined | -5.43 M undefined |
| 2006 | 6.9 M undefined | -2.53 M undefined | -2.75 M undefined |
| 2005 | 3.28 M undefined | -1.9 M undefined | -3.36 M undefined |
| 2004 | 510,000 undefined | -1.1 M undefined | -2.55 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 510,000 AUD | -1.1 M AUD | -2.55 M AUD |
| 2005 | 3.28 M AUD | -1.9 M AUD | -3.36 M AUD |
| 2006 | 6.9 M AUD | -2.53 M AUD | -2.75 M AUD |
| 2007 | 7.19 M AUD | -5.14 M AUD | -5.43 M AUD |
| 2008 | 2.98 M AUD | -2.38 M AUD | -5.77 M AUD |
| 2009 | 3.73 M AUD | 1.35 M AUD | -180,000 AUD |
| 2010 | 1.94 M AUD | -330,000 AUD | -440,000 AUD |
| 2011 | 1.6 M AUD | -790,000 AUD | -5.8 M AUD |
| 2012 | 1.63 M AUD | -880,000 AUD | -4.26 M AUD |
| 2013 | 1.72 M AUD | -610,000 AUD | -510,000 AUD |
| 2014 | 2.01 M AUD | -1.32 M AUD | -1.32 M AUD |
| 2015 | 2.42 M AUD | -1.92 M AUD | -1.93 M AUD |
| 2016 | 2.75 M AUD | -1.82 M AUD | -3.93 M AUD |
| 2017 | 3.33 M AUD | -1.28 M AUD | -1.34 M AUD |
| 2018 | 3.3 M AUD | -2.49 M AUD | -2.52 M AUD |
| 2019 | 4.36 M AUD | -1.5 M AUD | -1.55 M AUD |
| 2020 | 4.12 M AUD | -1.24 M AUD | -1.36 M AUD |
| 2021 | 3.67 M AUD | -1.26 M AUD | -1.34 M AUD |
| 2022 | 4.51 M AUD | -1.62 M AUD | -1.71 M AUD |
| 2023 | 3.9 M AUD | -2.62 M AUD | -6.21 M AUD |
Pharmaust stock margins AU000000PAA1 · A0DNJ3
The Pharmaust margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pharmaust. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pharmaust.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Pharmaust's sales revenue. A higher gross margin percentage indicates that the Pharmaust retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Pharmaust's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Pharmaust's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pharmaust's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pharmaust. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pharmaust's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Pharmaust Margin History
| Pharmaust Gross margin | Pharmaust Profit margin | Pharmaust EBIT margin | Pharmaust Profit margin |
|---|---|---|---|
| 2023 | 79.81 % | -67.28 % | -159.26 % |
| 2022 | 93.03 % | -35.91 % | -37.87 % |
| 2021 | 93.86 % | -34.27 % | -36.42 % |
| 2020 | 94.03 % | -30.16 % | -33.03 % |
| 2019 | 92.36 % | -34.45 % | -35.54 % |
| 2018 | 91.22 % | -75.65 % | -76.51 % |
| 2017 | 89.78 % | -38.52 % | -40.31 % |
| 2016 | 91.49 % | -65.91 % | -142.56 % |
| 2015 | 91.41 % | -79.4 % | -79.55 % |
| 2014 | 88.56 % | -65.67 % | -65.67 % |
| 2013 | 87.21 % | -35.47 % | -29.65 % |
| 2012 | 88.96 % | -53.99 % | -261.35 % |
| 2011 | 91.25 % | -49.38 % | -362.5 % |
| 2010 | 89.18 % | -17.01 % | -22.68 % |
| 2009 | 94.91 % | 36.19 % | -4.83 % |
| 2008 | 76.17 % | -79.87 % | -193.62 % |
| 2007 | 58 % | -71.49 % | -75.52 % |
| 2006 | 71.59 % | -36.67 % | -39.86 % |
| 2005 | 59.76 % | -57.93 % | -102.44 % |
| 2004 | 72.55 % | -215.69 % | -500 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 72.55 % | -215.69 % | -500 % |
| 2005 | 59.76 % | -57.93 % | -102.44 % |
| 2006 | 71.59 % | -36.67 % | -39.86 % |
| 2007 | 58 % | -71.49 % | -75.52 % |
| 2008 | 76.17 % | -79.87 % | -193.62 % |
| 2009 | 94.91 % | 36.19 % | -4.83 % |
| 2010 | 89.18 % | -17.01 % | -22.68 % |
| 2011 | 91.25 % | -49.38 % | -362.5 % |
| 2012 | 88.96 % | -53.99 % | -261.35 % |
| 2013 | 87.21 % | -35.47 % | -29.65 % |
| 2014 | 88.56 % | -65.67 % | -65.67 % |
| 2015 | 91.41 % | -79.4 % | -79.55 % |
| 2016 | 91.49 % | -65.91 % | -142.56 % |
| 2017 | 89.78 % | -38.52 % | -40.31 % |
| 2018 | 91.22 % | -75.65 % | -76.51 % |
| 2019 | 92.36 % | -34.45 % | -35.54 % |
| 2020 | 94.03 % | -30.16 % | -33.03 % |
| 2021 | 93.86 % | -34.27 % | -36.42 % |
| 2022 | 93.03 % | -35.91 % | -37.87 % |
| 2023 | 79.81 % | -67.28 % | -159.26 % |
Pharmaust Aktienanalyse
What does Pharmaust do?
Pharmaust Ltd is a biotechnology company based in Perth, Australia. The company was founded in 2001 by Dr. Roger Aston and Dr. Paul Gavin as a spin-off from the School of Biomedical Sciences at Curtin University of Technology. Their goal was to advance the discovery and development of novel therapeutics and diagnostics for cancer and autoimmune diseases. Pharmaust's history began with the discovery of a novel molecule called PPL-1 by Dr. Roger Aston. This molecule had the potential to serve as a cancer therapeutic as it could inhibit the release of tumor cells. Pharmaust researchers held patents for PPL-1 in the US, Europe, and Australia. Another important milestone for Pharmaust was the discovery of a new class of compounds with potential cancer and autoimmune therapeutics known as PPL-100, PPL-300, and PPL-400. Pharmaust's business model is focused on bringing novel drugs and diagnostics to market and selling them. Pharmaust aims to use its technologies to reduce the high costs of drug research and ultimately help patients suffering from serious diseases. Pharmaust has several divisions, including: - Pharmaceutical research and development: Pharmaust is working to discover and develop new therapeutics and diagnostics, particularly for the treatment of cancer and autoimmune diseases. - Clinical research: Pharmaust conducts clinical trials to assess the safety and efficacy of its drugs and obtain the necessary approvals for market authorization. - Licensing and marketing: Pharmaust markets its products in Australia and other countries, and licenses its technologies to other biopharmaceutical companies to generate additional revenue. Pharmaust's current product portfolio includes two main products sold under the brand names Monepantel and PPL-003. Monepantel is an anthelmintic used to treat parasite infestation in livestock such as sheep and goats. PPL-003 is an immunotherapy for the treatment of skin cancer, currently being tested in clinical trials. In particular, Pharmaust has developed a therapy in recent years that supports immunotherapy and works closely with clinics and payers to further develop and market their therapy. Pharmaust has received numerous awards and recognitions in recent years, including the award for Perth's Best Emerging Company and recognition from the Western Australian Industry and Export Awards (WAIEA) and the Australasian Society for Stem Cell Research (ASSCR). In conclusion, Pharmaust Ltd remains committed to saving and improving lives. The company sees a promising future in the discovery, development, and marketing of novel therapeutics and diagnostics for the treatment of serious diseases. By integrating four different drug classes, Pharmaust is working on a range of early-stage development projects that have the potential to help patients suffering from various diseases. Pharmaust ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Pharmaust's Sales Figures
The sales figures of Pharmaust originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Pharmaust’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Pharmaust's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Pharmaust’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Pharmaust stock
How much was the turnover of the company Pharmaust compared to the previous year?
The revenue of Pharmaust has increased by -13.53% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Pharmaust?
The revenue of Pharmaust is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Pharmaust measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Pharmaust so important for investors?
The revenue of Pharmaust is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Pharmaust pay?
Over the past 12 months, Pharmaust paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharmaust is expected to pay a dividend of 0 AUD.
What is the dividend yield of Pharmaust?
The current dividend yield of Pharmaust is .
When does Pharmaust pay dividends?
Pharmaust pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Pharmaust?
Pharmaust paid dividends every year for the past 0 years.
What is the dividend of Pharmaust?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Pharmaust located?
Pharmaust is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharmaust kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharmaust from 9/10/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did Pharmaust pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of Pharmaust in the year 2023?
In the year 2023, Pharmaust distributed 0 AUD as dividends.
In which currency does Pharmaust pay out the dividend?
The dividends of Pharmaust are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Pharmaust
Our stock analysis for Pharmaust Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmaust Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
